Cafepharma Today

January 27 2025 - Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Metsera eyes $289M IPO to fund phase 3 weight loss trial
Biogen, Eisai win nod for monthly Leqembi maintenance amid stagnant sales
Sara Brenner, FDA device official, named agency’s acting head
*please scroll down for all the latest news*

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

*please scroll down for all the latest news*

Current News

submit a press release

Sanofi-Aventis reveals targets for expansion
FT.com
Wednesday, February 11, 2009 - 7:10am
tags:
Sanofi
FDA delays decision on approving J&J's Risperdal Consta for bipolar disorder
Yahoo/AP
Wednesday, February 11, 2009 - 7:09am
tags:
FDA, JNJ, bipolar disorder, Risperdal Consta
DNA, Roche Analysts Show Their Loyalties
TheStreet.com
Tuesday, February 10, 2009 - 5:56pm
tags:
Genentech, Roche, buyouts
J&J’s Prozac Cousin Approved Overseas, But Not for Depression
WSJ Online
Tuesday, February 10, 2009 - 5:55pm
tags:
JNJ, Prozac, Priligy
How will Kindler mix Wy-Pfi? Very carefully
Fierce Pharma
Tuesday, February 10, 2009 - 5:00pm
tags:
Jeff Kindler, Pfizer, Wyeth, buyouts
What the Pfizer-Wyeth Deal Has to Do With the Supreme Court
WSJ Online
Tuesday, February 10, 2009 - 4:59pm
tags:
Pfizer, Wyeth
Allergan Holding Steady
Yahoo/Zacks.com
Tuesday, February 10, 2009 - 4:57pm
tags:
Allergan
Dr. Reddy's Labs Range-Bound
Yahoo/Zacks.com
Tuesday, February 10, 2009 - 4:57pm
tags:
Dr Reddy's
Teva gets approval for generic Imitrex tablets
Yahoo/AP
Tuesday, February 10, 2009 - 4:56pm
tags:
Teva Pharmaceuticals, Imitrex, migraines, generics
Sanofi May Cut EU1 Billion in Costs, Buy Biotechs
Bloomberg
Tuesday, February 10, 2009 - 9:10am
tags:
Sanofi, biotech, buyouts
NICE deal, Celegene
InVivo
Tuesday, February 10, 2009 - 8:27am
tags:
NICE, UK, Celegene, Revlimid
Enzon Announces IND Acceptance for Its Survivin Antagonist
Yahoo
Tuesday, February 10, 2009 - 8:25am
tags:
Enzon, Survivin antagonist, cancer
An Increase in Healthcare M&A Doesn't Yet Signal a Bottom
Seeking Alpha
Tuesday, February 10, 2009 - 8:23am
tags:
buyouts
Bond markets squeeze pharma dealmakers
Fierce Pharma
Tuesday, February 10, 2009 - 7:47am
tags:
bonds, buyouts, pharma industry, Pfizer, Roche
OSI Pharmaceuticals Announces Notification of ANDA Filing for Tarceva
Yahoo
Tuesday, February 10, 2009 - 7:41am
tags:
OSI Pharmaceuticals, Teva Pharmaceuticals, ANDAs, Tarceva
FDA seeks plans to reduce misuse of painkillers
Yahoo/AP
Tuesday, February 10, 2009 - 7:39am
tags:
painkillers, FDA, King, Embeda, Pain Therapeutics
Buying Wyeth would boost Pfizer's revenues, but it won't help with the litany of marketing challenges and other problems plaguing Big Pharma
Businessweek
Tuesday, February 10, 2009 - 7:38am
tags:
Wyeth, Big Pharma, Pfizer, buyouts
Genentech Asked Roche to Pay $112/Share
TheStreet.com
Tuesday, February 10, 2009 - 7:08am
tags:
Genentech, Roche, buyouts
For Antidepressants, Maybe Three Targets Will Be Better than Two
WSJ Online
Tuesday, February 10, 2009 - 7:07am
tags:
antidepressants, TRIs, Neurosearch, AstraZeneca, Bristol-Myers Squibb, Dov
Have Pfizer and Wyeth Considered Their Competing Products?
Seeking Alpha
Tuesday, February 10, 2009 - 7:05am
tags:
Pfizer, Wyeth, buyouts, Celebrex, Enbrel, FTC

Pages

Latest CP Wire Articles

FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies
Sapio Sciences launches new drug discovery platform
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Why Medical and Pharma Sales Reps Should Start Their Own Senior Care Business

Latest Pharmagather Articles

Attacking Estrogen-Receptor-Positive Breast Cancer
In the Pipeline
New Study Reveals Five Crucial Priorities Shaping The Future of Patient Services
Drug Channels
Killing Cancer Patients (Once the Payments Clear)
In the Pipeline
The Big Three PBMs’ 2025 Formulary Exclusions: Humira, Stelara, Private Labels, and the Shaky Future for Pharmacy Biosimilars
Drug Channels
Clinical Trial Readouts Are A-Comin'
In the Pipeline
The Current Environment
In the Pipeline
Informa Connect's Patient Assistance & Access Programs (PAP)
Drug Channels
2025 Brand Drug Challenges: A GoodRx Perspective
Drug Channels
Snake Antivenoms, Computed
In the Pipeline

Latest Jobs

Onsite Endoscopic Specialist - Operating Room Support
Santa Monica, California
KARL STORZ Endoscopy - America
Area Manager, Immunology Rochester, NY Territory
Fields, Oregon, 97710
CSL Behring
Psychiatry Account Manager - Tarrytown, NY
Tarrytown, New York
Lundbeck
Area Manager Specialty, West- Central
Fields, Oregon, 97710
CSL Behring
Area Sale Manager, Immunology Tampa North
Fields, Oregon, 97710
CSL Behring
Sales Representative
Boise, Idaho, 83708
Bartlett Roofing
Capital Project Manager
Carteret, New Jersey, United States
The Spear Group
Area Manager Specialty, West
Fields, Oregon, 97710
CSL Behring
Psychiatry Account Manager - Midland, TX
Midland, Texas, 79701
Lundbeck
Home Health and Medical Sales
The Woodlands, Texas, 77381
Comfort Keepers of Dallas TX
more jobs

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.

Do Not Allow Advertisers to Use My Personal information